Navigation Links
Stephens Initiates Coverage on Vermillion
Date:3/25/2011

AUSTIN, Texas, March 25, 2011 /PRNewswire/ -- (Nasdaq: VRML) – Vermillion, a molecular diagnostics company, announced today that Stephens, Inc. initiated analyst coverage March 23, 2011 on Vermillion.

This research report may be obtained directly from the analyst at Stephens by contacting, Scott Gleason at scott.gleason@stephens.com.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Additional information about Vermillion can be found on the Web at www.vermillion.com.

About OVA1®

OVA1® is a qualitative serum test that combines the results of five immunoassays into a single numerical score. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The test utilizes five well-established biomarkers - Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), Beta 2-Microglobulin (Beta 2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) - and a proprietary FDA-cleared software device to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned. Additional information about OVA1® can be found on the Web at www.ova-1.com.

Forward-Looking Statement

Certain matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion will successfully license or otherwise successfully partner with third parties to commercialize its future products; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (7) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.

This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q. Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at www.sec.gov.


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genomic Health to Present at Stephens Fall Investment Conference
2. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
7. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
8. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
9. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
10. SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia
11. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2019)... ... March 04, 2019 , ... Stay on top of current hot topics through free webinars ... webinars is free, so be sure to register today to save your place! Participate in ... our upcoming webinars: , CLINICAL TRIALS, , March 20 – Implementing ...
(Date:2/27/2019)... , ... February 26, 2019 , ... ... custom industrial automation and IT solutions with 140 employees on both the east ... professional engineer’s license in the State of New Hampshire. Sandmaier, a senior project ...
(Date:2/22/2019)... ... February 20, 2019 , ... ... , an emerging leader in the rapidly growing NGS (Next Generation Sequencing) field, ... Murrieta Genomics laboratory and incubator. , "As an innovation center and idea incubator, ...
(Date:2/22/2019)... ... , ... Ocean Tomo Transactions, LLC will auction a portfolio ... in lot 92 relate to innovation for verifying human users through ... and computers through exploiting the fundamental differences between computer-based vision and human visual ...
Breaking Biology Technology:
(Date:2/27/2019)... Calif. (PRWEB) , ... February 27, 2019 , ... Fluxion ... announced that it has received a National Cancer Institute grant for further development of ... 9 months, with clinical support from the lab of Dr. Omar Mian at the ...
(Date:2/22/2019)... ... 2019 , ... Clean label food is not just another passing trend in ... It is quite common to spot consumers running their index finger across the back ... this label scrutiny. , More than ever, meat and poultry producers are working ...
(Date:2/19/2019)... ... February 19, 2019 , ... BioInformatics ... Hozza as Chief Commercial Officer of the life science research and advisory firm. ... strategy, and alignment of all market research and media revenue operations in the ...
Breaking Biology News(10 mins):